Want to see GOVX full AI Analyst Report?
GOVX Stock Chart & Stats
$3.57
-$0.19(-7.85%)
At close: 4:00 PM EST
$3.57
-$0.19(-7.85%)
Day’s Range― - ―
52-Week Range$0.96 - $23.10
Previous CloseN/A
Volume281.82K
Average Volume (3M)811.20K
Market Cap
$6.10M
Enterprise Value$253.80K
Total Cash (Recent Filing)$1.27M
Total Debt (Recent Filing)$394.57K
Price to Earnings (P/E)―
Beta3.43
Next Earnings
Aug 12, 2026EPS Estimate
-2.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-21.67
Shares Outstanding5,210,465
10 Day Avg. Volume209,268
30 Day Avg. Volume811,201
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.07
Price to Sales (P/S)1.65
P/FCF Ratio-0.19
Enterprise Value/Market Cap0.04
Enterprise Value/Revenue0.30
Enterprise Value/Gross Profit-0.02
Enterprise Value/Ebitda-0.01
Forecast
1Y Price Target
$10.00Price Target Upside180.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-9.28
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical StudiesAdditional data announcements from clinical studies with 04S1 could be positive catalysts through 2025.
Comparative AnalysisDSMB Review Suggests GEO-CM04S1 May Be Superior to mRNA Vaccine.
Vaccine DevelopmentGEO-CM04S1 booster studies to continue, with early clinical studies showing the vaccine induces durable neutralizing antibody and T-cell-based immunity against current and future variants of SARS-CoV-2.
Bears Say
Contract TerminationTermination of the contract will not have a long-term material effect.
Project TerminationGeoVax Labs announced it received written notification from Advanced Technology International directing GeoVax to stop work on all efforts with respect to a Rapid Response Partnership Vehicle project.
GeoVax Labs News
GOVX FAQ
What was Geovax Labs, Inc.’s price range in the past 12 months?
Geovax Labs, Inc. lowest stock price was $0.96 and its highest was $23.10 in the past 12 months.
What is Geovax Labs, Inc.’s market cap?
Geovax Labs, Inc.’s market cap is $6.10M.
When is Geovax Labs, Inc.’s upcoming earnings report date?
Geovax Labs, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 32 days.
How were Geovax Labs, Inc.’s earnings last quarter?
Geovax Labs, Inc. released its earnings results on Apr 30, 2026. The company reported -$2.62 earnings per share for the quarter, the consensus estimate of -$2.62 by $0.
Is Geovax Labs, Inc. overvalued?
According to Wall Street analysts Geovax Labs, Inc.’s price is currently Undervalued.
Does Geovax Labs, Inc. pay dividends?
Geovax Labs, Inc. does not currently pay dividends.
What is Geovax Labs, Inc.’s EPS estimate?
Geovax Labs, Inc.’s EPS estimate is -2.16.
How many shares outstanding does Geovax Labs, Inc. have?
Geovax Labs, Inc. has 5,210,465 shares outstanding.
What happened to Geovax Labs, Inc.’s price movement after its last earnings report?
Geovax Labs, Inc. reported an EPS of -$2.62 in its last earnings report, expectations of -$2.62. Following the earnings report the stock price went up 3.81%.
Which hedge fund is a major shareholder of Geovax Labs, Inc.?
Currently, no hedge funds are holding shares in GOVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Geovax Labs, Inc.
GeoVax Labs, Inc. is a biotechnology company in the clinical development phase, focused on creating innovative human vaccines and immunotherapies. The firm targets both infectious diseases and various cancer types, utilizing its proprietary modified vaccinia ankara (MVA) virus-like particle (VLP) vaccine platform. Its product pipeline includes several prophylactic vaccines aimed at preventing illnesses such as COVID-19, human immunodeficiency virus (HIV), Zika virus, malaria, and a range of hemorrhagic fevers like Ebola, Sudan, Marburg, and Lassa. Additionally, GeoVax is developing therapeutic vaccines designed to treat existing conditions, specifically HIV, chronic Hepatitis B infections, and solid tumor cancers. To support its research and development efforts, GeoVax Labs, Inc. has forged partnerships with notable organizations. These collaborators include the National Institute of Allergy and Infectious Diseases (part of the National Institutes of Health), the Centers for Disease Control and Prevention, the U.S. Department of Defense, Emory University, the University of Pittsburgh, and the Burnet Institute. Founded in 1988, GeoVax Labs, Inc. is headquartered in Smyrna, Georgia.
GOVX Stock 12 Month Forecast
Average Price Target
$10.00
▲(180.11% Upside)
Technical Analysis
Ownership Overview
3.54% Insiders
0.33% Mutual Funds
5.17% Other Institutional Investors
90.91% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---